Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while iShares 10 20 Year Treasury Bond ETF trades at $98.42. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | TLH | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Fixed Income |
52-Week High | $28.06 | $105.36 |
52-Week Low | $20.06 | $97.13 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TLH trades at $99.53, down 0.04% on the day, with technical indicators signaling a bearish trend. The stock shows no valuation or profitability metrics in the provided data, but upcoming dividends of $0.41 and $0.36 are scheduled for July 2026. Recent news highlights bond market volatility and Federal Reserve uncertainty, which may impact broader equity sentiment.
The outlook for TLH is cautious due to weak technical momentum and lack of fundamental data. Risks include macroeconomic pressures from potential rate hikes, while the dividend payments offer some income support. Investors should seek updated financials for a clearer assessment of the company's health and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
